Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Abbv crawled time : 14:30 save search
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.21%
H: 0.97%
C: 0.7%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.05%
H: 0.14%
C: -0.93%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -1.58%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.7%
H: 0.73%
C: -0.16%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.27%
H: 1.26%
C: 0.84%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.2%
H: 1.14%
C: -1.18%
antibody therapeutics market
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.73%
H: 0.78%
C: 0.35%
lung abbvie positive cancer cell topline trial results
AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
Published: 2023-09-12 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.31%
H: 0.07%
C: -0.15%
skyrizi disease study
AbbVie to Present at the Morgan Stanley Healthcare Conference - September 6, 2023
Published: 2023-09-06 (Crawled : 14:30) - biospace.com/
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: -1.87%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
conference abbvie
Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research
Published: 2023-09-01 (Crawled : 14:30) - prnewswire.com
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: -0.07%
H: 3.3%
C: 0.26%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
CPIX | $1.63 0.62% 0.61% 6.8K
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: 0.62%
H: 0.26%
C: -0.68%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: 0.86%
H: 0.16%
C: -0.38%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.91%
H: 0.14%
C: -0.76%
research market
Hematological Malignancies Emerging Therapeutics - A Global Industry Assessment with Insights & Projections by Therapeutic Type, Potential Pipeline Products, Indication, and Region, 2021-2031
Published: 2022-03-16 (Crawled : 14:30) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: -0.46%
H: 3.49%
C: 3.49%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 2.07%
H: 1.62%
C: 1.56%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.23%
H: 0.0%
C: 0.0%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.26%
H: 0.31%
C: -0.39%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.4%
H: 0.2%
C: -0.29%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -1.19%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: -0.37%
ema therapeutics potential
AbbVie to Present at the Cowen 42nd Annual Health Care Conference
Published: 2022-03-01 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
health conference
AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic Graft Versus Host Disease (cGVHD)
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
imbruvica disease
AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder
Published: 2022-02-22 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -1.93%
H: 3.61%
C: 3.05%
vraylar new drug treatment fda order application drug major depressive disorder
AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales for Rinvoq and Skyrizi in 2025
Published: 2022-01-11 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.81%
H: 0.0%
C: 0.0%
risk
AbbVie to Present at the Piper Sandler Healthcare Conference
Published: 2021-11-23 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: 0.0%
conference
Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting
Published: 2021-11-19 (Crawled : 14:30) - biospace.com/
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.48%
H: 0.14%
C: -1.18%
aesthetic
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.